Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar
Copyright © 2021 Massachusetts Medical Society..
BACKGROUND: Waning of vaccine protection against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection or coronavirus disease 2019 (Covid-19) is a concern. The persistence of BNT162b2 (Pfizer-BioNTech) vaccine effectiveness against infection and disease in Qatar, where the B.1.351 (or beta) and B.1.617.2 (or delta) variants have dominated incidence and polymerase-chain-reaction testing is done on a mass scale, is unclear.
METHODS: We used a matched test-negative, case-control study design to estimate vaccine effectiveness against any SARS-CoV-2 infection and against any severe, critical, or fatal case of Covid-19, from January 1 to September 5, 2021.
RESULTS: Estimated BNT162b2 effectiveness against any SARS-CoV-2 infection was negligible in the first 2 weeks after the first dose. It increased to 36.8% (95% confidence interval [CI], 33.2 to 40.2) in the third week after the first dose and reached its peak at 77.5% (95% CI, 76.4 to 78.6) in the first month after the second dose. Effectiveness declined gradually thereafter, with the decline accelerating after the fourth month to reach approximately 20% in months 5 through 7 after the second dose. Effectiveness against symptomatic infection was higher than effectiveness against asymptomatic infection but waned similarly. Variant-specific effectiveness waned in the same pattern. Effectiveness against any severe, critical, or fatal case of Covid-19 increased rapidly to 66.1% (95% CI, 56.8 to 73.5) by the third week after the first dose and reached 96% or higher in the first 2 months after the second dose; effectiveness persisted at approximately this level for 6 months.
CONCLUSIONS: BNT162b2-induced protection against SARS-CoV-2 infection appeared to wane rapidly following its peak after the second dose, but protection against hospitalization and death persisted at a robust level for 6 months after the second dose. (Funded by Weill Cornell Medicine-Qatar and others.).
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:385 |
|---|---|
| Enthalten in: |
The New England journal of medicine - 385(2021), 24 vom: 09. Dez., Seite e83 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Chemaitelly, Hiam [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
2019-nCoV Vaccine mRNA-1273 |
|---|
| Anmerkungen: |
Date Completed 22.12.2021 Date Revised 23.11.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1056/NEJMoa2114114 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM331553716 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM331553716 | ||
| 003 | DE-627 | ||
| 005 | 20231225213725.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1056/NEJMoa2114114 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1105.xml |
| 035 | |a (DE-627)NLM331553716 | ||
| 035 | |a (NLM)34614327 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Chemaitelly, Hiam |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 22.12.2021 | ||
| 500 | |a Date Revised 23.11.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2021 Massachusetts Medical Society. | ||
| 520 | |a BACKGROUND: Waning of vaccine protection against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection or coronavirus disease 2019 (Covid-19) is a concern. The persistence of BNT162b2 (Pfizer-BioNTech) vaccine effectiveness against infection and disease in Qatar, where the B.1.351 (or beta) and B.1.617.2 (or delta) variants have dominated incidence and polymerase-chain-reaction testing is done on a mass scale, is unclear | ||
| 520 | |a METHODS: We used a matched test-negative, case-control study design to estimate vaccine effectiveness against any SARS-CoV-2 infection and against any severe, critical, or fatal case of Covid-19, from January 1 to September 5, 2021 | ||
| 520 | |a RESULTS: Estimated BNT162b2 effectiveness against any SARS-CoV-2 infection was negligible in the first 2 weeks after the first dose. It increased to 36.8% (95% confidence interval [CI], 33.2 to 40.2) in the third week after the first dose and reached its peak at 77.5% (95% CI, 76.4 to 78.6) in the first month after the second dose. Effectiveness declined gradually thereafter, with the decline accelerating after the fourth month to reach approximately 20% in months 5 through 7 after the second dose. Effectiveness against symptomatic infection was higher than effectiveness against asymptomatic infection but waned similarly. Variant-specific effectiveness waned in the same pattern. Effectiveness against any severe, critical, or fatal case of Covid-19 increased rapidly to 66.1% (95% CI, 56.8 to 73.5) by the third week after the first dose and reached 96% or higher in the first 2 months after the second dose; effectiveness persisted at approximately this level for 6 months | ||
| 520 | |a CONCLUSIONS: BNT162b2-induced protection against SARS-CoV-2 infection appeared to wane rapidly following its peak after the second dose, but protection against hospitalization and death persisted at a robust level for 6 months after the second dose. (Funded by Weill Cornell Medicine-Qatar and others.) | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a COVID-19 Vaccines |2 NLM | |
| 650 | 7 | |a 2019-nCoV Vaccine mRNA-1273 |2 NLM | |
| 650 | 7 | |a EPK39PL4R4 |2 NLM | |
| 650 | 7 | |a BNT162 Vaccine |2 NLM | |
| 650 | 7 | |a N38TVC63NU |2 NLM | |
| 700 | 1 | |a Tang, Patrick |e verfasserin |4 aut | |
| 700 | 1 | |a Hasan, Mohammad R |e verfasserin |4 aut | |
| 700 | 1 | |a AlMukdad, Sawsan |e verfasserin |4 aut | |
| 700 | 1 | |a Yassine, Hadi M |e verfasserin |4 aut | |
| 700 | 1 | |a Benslimane, Fatiha M |e verfasserin |4 aut | |
| 700 | 1 | |a Al Khatib, Hebah A |e verfasserin |4 aut | |
| 700 | 1 | |a Coyle, Peter |e verfasserin |4 aut | |
| 700 | 1 | |a Ayoub, Houssein H |e verfasserin |4 aut | |
| 700 | 1 | |a Al Kanaani, Zaina |e verfasserin |4 aut | |
| 700 | 1 | |a Al Kuwari, Einas |e verfasserin |4 aut | |
| 700 | 1 | |a Jeremijenko, Andrew |e verfasserin |4 aut | |
| 700 | 1 | |a Kaleeckal, Anvar H |e verfasserin |4 aut | |
| 700 | 1 | |a Latif, Ali N |e verfasserin |4 aut | |
| 700 | 1 | |a Shaik, Riyazuddin M |e verfasserin |4 aut | |
| 700 | 1 | |a Abdul Rahim, Hanan F |e verfasserin |4 aut | |
| 700 | 1 | |a Nasrallah, Gheyath K |e verfasserin |4 aut | |
| 700 | 1 | |a Al Kuwari, Mohamed G |e verfasserin |4 aut | |
| 700 | 1 | |a Al Romaihi, Hamad E |e verfasserin |4 aut | |
| 700 | 1 | |a Butt, Adeel A |e verfasserin |4 aut | |
| 700 | 1 | |a Al-Thani, Mohamed H |e verfasserin |4 aut | |
| 700 | 1 | |a Al Khal, Abdullatif |e verfasserin |4 aut | |
| 700 | 1 | |a Bertollini, Roberto |e verfasserin |4 aut | |
| 700 | 1 | |a Abu-Raddad, Laith J |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The New England journal of medicine |d 1945 |g 385(2021), 24 vom: 09. Dez., Seite e83 |w (DE-627)NLM000008184 |x 1533-4406 |7 nnns |
| 773 | 1 | 8 | |g volume:385 |g year:2021 |g number:24 |g day:09 |g month:12 |g pages:e83 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1056/NEJMoa2114114 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 385 |j 2021 |e 24 |b 09 |c 12 |h e83 | ||